IDEXX Laboratories Inc (IDXX)
Days of sales outstanding (DSO)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | 7.72 | 7.62 | 7.29 | 7.25 | 7.50 | 8.13 | 7.65 | 7.72 | 8.29 | 7.97 | 7.62 | 7.21 | 7.71 | 7.16 | 7.36 | 7.80 | 8.30 | 8.14 | 8.01 | 8.01 | |
| DSO | days | 47.30 | 47.91 | 50.08 | 50.34 | 48.67 | 44.88 | 47.74 | 47.26 | 44.02 | 45.82 | 47.89 | 50.64 | 47.32 | 50.94 | 49.57 | 46.81 | 43.95 | 44.85 | 45.59 | 45.58 |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 7.72
= 47.30
Idexx Laboratories, Inc.'s days of sales outstanding (DSO) have shown some fluctuations over the past eight quarters. In Q4 2023, the DSO was 47.30 days, slightly lower than the previous quarter's 47.91 days. This suggests that the company was able to collect its accounts receivable more efficiently in Q4 2023.
Comparing Q4 2023 to the same quarter in the previous year, the DSO decreased from 48.67 days to 47.30 days, indicating an improvement in the collection of receivables year-over-year.
Overall, Idexx Laboratories, Inc. has managed its accounts receivable effectively, with DSO hovering around the mid-40s to low 50s range over the past eight quarters. This suggests that the company has been successful in collecting payments from customers within a reasonable timeframe, maintaining a healthy cash flow position.
Peer comparison
Dec 31, 2023